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Tumor-infiltrating lymphocytes (TILs) are vital in limiting cancer progression andmay supplement the TNM classification.
CD45RO+memory TILs showmajor prognostic impact in variousmalignancies but have not been extensively explored in
non–small cell lung cancer (NSCLC). In this study, we aimed to evaluate their potential in a NSCLC TNM-Immunoscore.
Tissue microarrays were constructed from tumor tissue samples from two cohorts including in total 536 patients
(University Hospital of North Norway, n= 285; Nordland Hospital, n= 251) with primary resected stage I to IIIA NSCLC.
The density of CD45RO+ and CD8+ TILs in tumor epithelial and stromal compartments of the tumors was evaluated by
immunohistochemistry. In univariate analyses, intraepithelial CD45RO+ TIL density (T-CD45RO) was a significant
prognostic factor for disease-specific survival (P=.007), limited to the squamouscell carcinoma (SCC)histology subgroup
(P b .001), where it was significant in both cohorts (University Hospital of North Norway, P= .003; NordlandHospital, P=
.022). Combining T-CD45ROand stromal CD8+ TIL density (S-CD8) increased the prognostic impact in SCC (P b .001) and
showed a significant impactwithin all pathological stages (I,P= .025; II,Pb .001; III,P=.001). In themultivariate analysis,
T-CD45ROwas an independent positive prognostic factor for SCC (hazard ratio 2.65, 95% confidence interval 1.64-4.28,
P b .001), and in combination with S-CD8, the prognostic impact increased vastly (high + high versus low + low: hazard
ratio 6.50, 95%confidence interval 3.54-11.91, P b .001). In conclusion, T-CD45ROwas an independent prognostic factor
for SCC NSCLC. When combined with S-CD8, the prognostic impact increased and was significant within each
pathological stage. We propose CD45RO as a candidate marker for TNM-Immunoscore in SCC NSCLC.
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Lung cancer is the most lethal malignancy worldwide, causing
approximately one in five cancer deaths [1]. To improve outcome for
patients with non–small cell lung cancer (NSCLC), there is an urgent
need for novel prognostic factors, which may assist medical decision
making by allowing individualized risk stratification and contribute to
the discovery of novel treatment options.
840 Paulsen et al. Neoplasia Vol. 17, No. 11, 2015Data on tumor burden (T), presence of cancer cells in regional
lymph nodes (N), and evidence of metastases (M) are combined in
the American Joint Committee on Cancer/Union Internationale
Contre le Cancer TNM classification. Together with histological
subtyping, the TNM classification is currently the best determinant
of the NSCLC patient prognosis available, supplying the most reliable
guidelines for treatment decision making. Nevertheless, a supplement
to the TNM status is warranted because clinical outcome may vary
significantly among patients within the same pathological stage [2].
Immune cell infiltration can critically influence cancer patient
outcome [3], and studies of the “immune contexture”, defined as the
type, density, and location of immune cells, have allowed the
identification of immune cell subsets influencing prognosis in
favorable as well as deleterious ways [3,4]. Tumor-infiltrating
lymphocytes (TILs), especially, have in many human malignancies
been associated with improved survival [3]. In colorectal cancer, a
combination of the density and location of CD3+, CD45RO+, and
CD8+ TILs was found to predict outcome. This combination was
independent of, and more powerful than, the standard pathological
TNM classification [5,6]. Presently, an international consortium is
prospectively validating and promoting the Immunoscore (TNM-I)
in the routine clinical colorectal cancer setting [7]. Furthermore, in
breast cancer, stromal TILs were found to be predictive of treatment
effect, and consensus recommendations for the evaluation of TILs in
breast cancer research and clinical trials have been issued [8].
In NSCLC, several studies have investigated the importance of the
immune contexture. Positive associations with survival have been
found for tumors with infiltration of immune cells, most consistently
CD3+, CD4+, and CD8+ T-lymphocytes, but also CD20+ and
tertiary lymphoid structures (TLS), all potential candidates of an
Immunoscore [3,9,10]. Recently, we as well as others have
demonstrated stromal CD8+ TIL density (S-CD8) to be a strong
independent prognostic factor for survival supplementing the TNM
classification [10,11]. To our knowledge, CD8 is so far the only
prognostic marker validated in a NSCLC TNM-I setting. However,
further validation in prospective studies is needed before potential
clinical use.
CD45 functions as a protein tyrosine phosphatase in leukocyte
signaling, and isoforms are expressed in a cell-type specific manner,
depending on their stage of differentiation and activation [12].
T memory cells are CD45RO+ T lymphocytes which have
encountered antigen and respond faster and with increased intensity on
antigenic stimulation compared with (CD45RA+) naïve T cells [13].
Based on the colorectal cancer TNM-I research, CD45RO+ TIL also
appears to be a candidate immune marker for NSCLC, for which its
prognostic role has been explored to a limited extent [14]. Thus, we
wanted to investigate the prognostic impact of Tmemory lymphocytes in
a large patient material of NSCLC. The aim of this study was to evaluate
the prognostic impact of CD45RO+ TIL density, alone and in
combination with CD8+ TIL density, in the tumor epithelial and
stromal compartments in primary resected stage I to IIIA NSCLC
patients, assessing its potential in an NSCLC TNM-I.
Materials and Methods
Patients and Clinical Samples
In this retrospective study, primary tumor tissues from patients
who underwent radical resection for NSCLC pathologic stage I to
IIIA at the University Hospital of North Norway (UNN) andNordland Hospital (NH) from 1990 through 2010, including a
recent expansion of patients treated during 2005 to 2010, were
collected and anonymized. The tumors were staged according to the
seventh edition International Union Against Cancer TNM classifi-
cation [15] and histologically classified according to theWorld Health
Organization guidelines on classification of lung cancer [16]. In this
period, 633 patients were diagnosed with NSCLC, according to the
hospital pathological databases. Ninety-seven patients were excluded
from the study because of 1) radiotherapy or chemotherapy before
surgery (n = 15), 2) other malignancy within 5 years before NSCLC
diagnoses (n = 39), 3) inadequate paraffin-embedded fixed tissue blocks
(n = 25), or 4) adenocarcinoma in situ, before 2011 classified as
bronchioloalveolar carcinoma (formerly known as BAC) ≤3 cm (n = 18)
[17]. Thus, 536 patients with complete medical records and adequate
paraffin-embedded tissue blocks were eligible. This report includes
follow-up data as of October 1, 2013. Median follow-up time of
survivors was 86months (range, 34-267months). TheNorwegianData
Protection Authority and the Regional Committee for Medical and
Health Research Ethics approved the study (Protocol ID: 2011/2503).
The reporting of clinicopathologic varables, survival data, and
biomarker expressions was conducted in accordancewith the REMARK
guidelines [18].
Microarray Construction
All cases were histologically reviewed by two pathologists (S.A.S.
and K.A.S.), and the most representative areas of viable neoplastic
epithelial cells and of tumor stroma were carefully selected. The tissue
microarrays (TMAs) were assembled using a tissue-arraying instru-
ment (Beecher Instruments, Silver Springs, MD). The detailed
methodology has been previously reported [19]. Briefly, we used a
0.6 mm–diameter stylet, and the study specimens were routinely
sampled with two replicate core samples from different areas of
neoplastic tissue and two of tumor stroma. Multiple 4-μm sections
were cut with a Micron microtome (HM355S) and stained by specific
antibodies for immunohistochemistry (IHC) analysis.
Immunohistochemistry
IHC assays for CD45RO were performed on Ventana Discovery
Ultra automated immunostainer (Ventana Medical Systems, Tucson,
AZ). Slides were deparaffinized in three 8-minute cycles. On-board
antigen retrieval was not required and excluded from protocol.
Endogenous peroxidase was blocked by Discovery inhibitor
(Cat#760-4840, Ventana) for 8 minutes. The primary antibody,
prediluted CD45RO mouse monoclonal antibody (Cat#790-2930,
clone UCHL1, Ventana), was applied, and slides were incubated for
20 minutes at 37°C. Slides were developed using Ultramap
anti-rabbit HRP (Cat#760-4315, Ventana) for 20 minutes and
were detected using ChromoMap DAB (Cat#760-159, Ventana).
Finally, to visualize the nuclei, slides were counterstained with
Ventana Hematoxylin II reagent for 8 minutes followed by a Bluing
reagent for 4 minutes and dehydrated, cleared, and mounted as in
routine processing.
The prognostic impact of CD8+ TILs has been previously published
in 335 of the patients in this cohort [11,20]. The expansion of the patient
material required renewed CD8 staining of the entire cohort (n = 536),
this time performed by a new clone of anti-CD8 antibody. The CD8
antibody (Cat# 790-4460, clone SP57, Roche) is well validated and in
routine clinical use at included hospitals. The staining method applied
has been previously described [11].
Figure 1. IHC analysis of NSCLC representing different scores for tumor cell and stromal expression. (A) Low intraepithelial CD45RO
score (SCC). (B) High intraepithelial CD45RO score (ADC). (C) Low stromal CD45RO score (ADC). (D) High stromal CD45RO score (SCC)
(magnification ×200). In most tumor cores, as well as in some stromal cores, there was a mixture of stromal cells and tumor cells.
However, by morphological criteria, we have scored only density of positive immune cells within the tumor epithelial compartment in
cores with tumor tissue present and density of positive immune stromal cells within cores with stromal tissue present.
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control staining of the sections with an isotype-matched control
antibody without the primary antibody was performed. Secondly,
multiple organ tissue microarray as positive and negative tissue
controls was used to verify the specificity of the staining in every
staining procedure. The positive tissue controls comprised tonsil and
lymph nodes, and negative tissue controls were samples of normal
brain tissue. For each antibody, staining was done in one single
experiment. Immunostaining was performed on adjacent sections to
allow comparison of regional distributions of TIL subset infiltrates.
Scoring of IHC
Samples from both cohorts were anonymized and independently
scored, under supervision of an experienced pathologist (S.A.S.) by,
for CD45RO, one pathologist (R.J.) and one biologist (M.R.) and,
for CD8, one biologist (M.R.) and one oncologist (E.P.). When
assessing one marker in a given core, both observers were blinded to
the scores of the other markers as well as to patient outcome. By light
microscopy, representative and viable tissue cores were scored
semiquantitatively for degree of infiltration of CD45RO+ or CD8+
lymphocytes. Manually, the percentages of CD45RO+ and CD8+
lymphocytes compared with the total amount of nucleated cells
(density) in the stromal and tumor epithelial compartments of each
core were assessed separately. Based on our previous experience [11],
scoring cutoffs for the density of CD8+ TILs in the stromal
compartment was set as follows; 0% to 5% positive cells = 0, 6% to
25% = 1, 26% to 50% = 2, and N50% = 3. In the epithelial
compartment, where immune cells were more sparse, scoring cutoffs
were set as follows: absent = 0, 1% to 5% = 1, 6% to 25% =2, 26% to
50% = 3. The same scoring method was used for CD45RO
(Figure 1). No cores had a T-CD45RO score of N2.The maximum score approach, defined as the single highest score
of the scores available, has been previously validated for S-CD8 [11].
Our aim was to compare and combine CD45RO scores with CD8
scores; thus, we present maximum scores for both. Based on a
minimal P value approach, high T-CD45RO was defined as a
maximum score of ≥1, and a maximum score of ≥2 was defined as
high for S-CD8, CD8+ TILs in epithelium (T-CD8), and
CD45RO+ TILs in stroma (S-CD45RO).
Statistical Methods/Considerations
All statistical analyses were performed using the SPSS statistical
package (version 22; SPSS, Chicago, IL). The IHC scores from each
observer were compared for interobserver reliability by use of a
two-way random effects model with absolute agreement definition.
The intraclass correlation coefficient (reliability coefficient) was
obtained from these results. Disease-specific survival (DSS), disease-
free survival (DFS), and overall survival (OS) were defined as the time
from surgery to lung cancer death, to first lung cancer relapse, and to
death of any cause, respectively.
The χ2 test or the Fisher exact test was used to examine the
association between molecular marker expression and various
clinicopathological parameters, applying Monte Carlo simulation
when expected values were b5 in N20% of cells (confidence level
95%, 10,000 samples, two-sided value). Spearman rank correlation
was used to examine the associations between marker expressions.
Univariate analysis of survival according to CD45RO+ or CD8+ TIL
density was done using the Kaplan-Meier method, and statistically
significant differences between survival curves were assessed by the
log-rank test. Multivariate analysis was performed using the Cox
proportional hazards model, testing the simultaneous influence on
survival of all covariates found to be significant in the univariate
Table 1. Clinicopathologic Variables as Predictors of DSS in 536 NSCLC Patients (Univariate Analyses; Log-Rank Test, Unadjusted Cox Proportional Hazard Ratios)
All Patients SCC ADC
N (%) 5 Years Median HR(95% CI) P N (%) 5 Years Median HR(95% CI) P N (%) 5 Years Median HR(95% CI) P
Age .711 .654 .505
≤65 227 (42) 57 127 1 106 (37) 64 235 1 102 (51) 48 54 1
N65 309 (58) 58 NA 0.95 (0.73-1.24) 183 (63) 66 NA 0.91 (0.61-1.36) 99 (49) 49 57 0.87 (0.59-1.3)
Sex .026 .108 .050
Female 170 (32) 63 190 1 73 (25) 73 NA 1 83 (41) 56 190 1
Male 366 (68) 55 88 1.4 (1.06-1.84) 216 (75) 63 235 1.49 (0.96-2.31) 118 (59) 43 51 1.5 (1.01-2.23)
ECOG perf. status .015 .158 .003
0 310 (58) 62 235 1 158 (55) 69 235 1 122 (61) 56 NA 1
1 190 (35) 52 71 1.45 (1.09-1.93) 110 (38) 61 114 1.47 (0.97-2.23) 67 (33) 40 50 1.57 (1.02-2.4)
2 36 (7) 48 36 1.61 (0.83-3.09) 21 (7) 67 NA 1.08 (0.45-2.6) 12 (6) 17 25 3.25 (0.96-11.03)
Smoking .039 .19 .68
Never 17 (3) 44 20 1 7 (2) 50 19 1 9 (5) 44 21 1
Previous 342 (64) 62 235 0.56 (0.25-1.24) 182 (63) 69 235 0.58 (0.14-2.37) 125 (62) 50 68 0.69 (0.26-1.84)
Present 177 (33) 51 71 0.75 (0.33-1.7) 100 (35) 60 114 0.82 (0.2-3.41) 67 (33) 45 57 0.73 (0.27-1.99)
Weight loss .961 .689 .536
b10% 480 (90) 58 127 1 257 (89) 66 235 1 184 (92) 49 57 1
≥10% 55 (10) 59 NA 0.99 (0.63-1.56) 32 (11) 62 NA 1.14 (0.57-2.28) 17 (8) 40 47 1.24 (0.59-2.63)
Surgical procedure b .001 b .001 b .001
Wedge/lobectomy 394 (74) 63 190 1 197 (68) 72 235 1 161 (80) 54 104 1
Pulmonectomy 142 (26) 42 30 1.98 (1.43-2.74) 92 (32) 50 35 1.99 (1.28-3.09) 40 (20) 25 24 2.66 (1.46-4.84)
Margins .129 .252 .018
Free 489 (91) 59 190 1 257 (89) 67 235 1 189 (94) 50 68 1
Not free 47 (9) 47 57 1.39 (0.85-2.29) 32 (11) 57 114 1.39 (0.73-2.63) 12 (6) 0 35 2.33 (0.81-6.69)
Tstage b .001 b .001 b .001
1 168 (31) 72 235 1 83 (29) 78 235 1 74 (37) 67 190 1
2 265 (49) 57 91 1.74 (1.3-2.32) 147 (51) 66 NA 1.88 (1.22-2.89) 94 (47) 43 47 1.94 (1.27-2.95)
3 97 (18) 36 30 2.84 (1.87-4.31) 56 (19) 46 33 2.93 (1.62-5.31) 31 (15) 16 25 3.48 (1.76-6.9)
4 6 (0) 20 15 4.89 (0.89-26.9) 3 (1) 0 10 17.41 (0.22-1371.77) 2 (1) 50 13 1.76 (0.23-13.27)
Nstage b .001 b .001 b .001
0 364 (68) 69 235 1 198 (69) 77 235 1 133 (66) 60 190 1
1 118 (22) 36 35 2.76 (1.93-3.94) 73 (25) 45 35 3.26 (1.99-5.35) 39 (19) 25 30 2.41 (1.38-4.2)
2 54 (10) 21 19 4.23 (2.43-7.37) 18 (6) 18 13 7.12 (2.44-20.77) 29 (15) 23 24 2.88 (1.42-5.82)
Pathological stage b .001 b .001 b .001
I 256 (48) 72 235 1 127 (44) 82 235 1 105 (52) 65 190 1
II 194 (36) 53 84 1.89 (1.42-2.51) 126 (44) 60 114 2.5 (1.66-3.77) 56 (28) 34 43 2.07 (1.3-3.28)
IIIA 86 (16) 20 17 4.58 (2.87-7.32) 36 (12) 23 15 7.15 (3.23-15.84) 40 (20) 16 24 3.37 (1.8-6.33)
Histology .040
SCC 289 (54) 65 235 1
ADC 201 (37) 48 57 1.43 (1.08-1.89)
LCC 46 (9) 50 83 1.29 (0.8-2.08)
Differentiation b .001 .033 .006
Poor 231 (43) 49 51 1 104 (36) 57 84 1 81 (40) 38 43 1
Moderate 240 (45) 63 190 0.67 (0.5-0.89) 155 (54) 70 235 0.63 (0.41-0.97) 85 (42) 50 68 0.69 (0.44-1.07)
Well 65 (12) 70 NA 0.44 (0.29-0.66) 30 (10) 72 NA 0.47 (0.24-0.94) 35 (18) 69 NA 0.36 (0.21-0.63)
Vascular
infiltration
b .001 .029 .012
No 437 (82) 62 235 1 231 (80) 69 235 1 172 (86) 52 71 1
Yes 97 (18) 38 35 1.89 (1.29-2.78) 58 (20) 53 71 1.65 (0.97-2.82) 27 (13) 26 27 1.9 (1-3.62)
Missing 2 (0) 2 (1)
Note: Bold numbers are significant results. Five-year survival (%). Median survival (months). Abbreviations: ECOG perf. status, Eastern Cooperative Oncology Group performance status; N, number;
Nstage, nodal stage; Tstage, tumor stage.
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method. Probability for stepwise entry and removal was set at .05 and
.10, respectively. P values b .05 were considered statistically significant.
Results
Patient Characteristics
Demographic, clinical, and histopathological variables are presented
in Table 1. Median age was 67 (range 28-85) years. The majority of
patients weremen (68%), but the rate of women increased from24% to
44% from the period 1990 to 2004 to the period 2005 to 2010. The
NSCLC tumors comprised 289 squamous cell carcinomas (SCCs), 201
adenocarcinomas (ADCs), and 46 large-cell carcinomas (LCCs).
Seventy-six patients (14%) received postoperative radiotherapy, and43 patients (20%) were given adjuvant chemotherapy during 2005 to
2010 (1990-2004: data not registered).
Density of CD45RO+ and CD8+ TILs and Their Correlations
The density of CD45RO+ and CD8+ TILs is presented in Table 2.
There was a significant correlation between the maximum score of
T-CD45RO and S-CD45RO (r = 0.494, P b .001). T-CD45RO
was significantly correlated with T-CD8 and S-CD8 (r = 0.265,
and 0.223, both P b .001). S-CD45RO was significantly
correlated with T-CD8 and S-CD8 (r = 0.252 and 0.559, both
P b .001). There were no major differences in clinicopathological
characteristics between patients with high versus low CD45RO score
in the total material as well as in the SCC and ADC subgroups
(Supplementary Table 1).
Table 2. The Prognostic Impact of Tumor Epithelial and Stromal CD45RO+ and CD8+ TILs on DSS in All Patients and Stratified by Histology (Univariate Analyses; Log-Rank Test, Unadjusted Cox
Proportional Hazard Ratios)
All Patients SCC ADC
N (%) 5 Years Median HR (95% CI) P N (%) 5 Years Median HR (95% CI) P N (%) 5 Years Median HR (95% CI) P
T-CD45RO .007 .0003 .843
High 423 (79) 59 190 1 226 (78) 69 235 1 162 (81) 48 57 1
Low 81 (15) 45 36 1.62 (1.14-2.29) 46 (16) 42 30 2.34 (1.46-3.77) 29 (14) 48 51 1.06 (0.59-1,91)
Missing 32 (6) 17 (6) 10 (5)
S-CD45RO .050 .012 .742
High 290 (54) 61 235 1 157 (54) 72 235 1 109 (54) 49 57 1
Low 225 (42) 53 75 1.31 (1.00-1.72) 123 (43) 57 NR 1.67 (1.12-2.50) 83 (41) 45 54 1.17 (0.71-1.60)
Missing 21 (4) 9 (3) 9 (5)
T-CD8 .036 .015 1 .943
High 146 (27) 66 235 1 78 (27) 78 235 1 53 (26) 49 57
Low 359 (67) 53 91 1.39 (1.02-1.90) 196 (68) 59 NR 1.81 (1.16-2.95) 136 (68) 47 57 1.02 (0.65-1.59)
Missing 31 (6) 15 (5) 12 (6)
S-CD8 .0002 .0002 .320
High 370 (69) 63 235 1 204 (70) 73 235 1 137 (68) 50 73 1
Low 148 (28) 44 47 1.70 (1.28-2.26) 77 (27) 46 41 2.17 (1.43-3.29) 57 (28) 42 50 1.24 (0.81-1.90)
Missing 18 (3) 8 (3) 7 (4)
T-CD45R0+ S-CD8 .0001 b .0001 .466
High + high 315 (62) 64 235 1 175 (65) 74 235 1 117 (62) 76 73 1
Intermediate 153 (31) 47 51 1.60 (1.19-2.14) 74 (27) 56 105 1.66 (1.04-2.64) 63 (33) 51 50 1.10 (0.40-3.05)
Low + low 34 (7) 37 28 2.36 (1.45-3.84) 22 (8) 19 18 4.77 (2.66-8.56) 10 (5) 41 71 1.42 (0.50-4.00)
Note: Bold numbers are significant results. Five-year survival (%). Median survival (months). Abbreviations: NR, not reached; S, stroma; T, tumor.
Neoplasia Vol. 17, No. 11, 2015 Paulsen et al. 843Interobserver Reliability
The interobserver reliability coefficients indicated moderate to
excellent agreement between scorers: intraclass correlation
coefficient for S-CD45RO, 0.889 (P b .001); for T-CD45RO,
0.642 (P b .001); for S-CD8, 0.878 (P b .001); and for T-CD8,
0.760 (P b .001).
Univariate Analyses: Prognostic Impact of Memory TILs in
Tumor and Stroma
Results of the univariate analyses are presented in Table 2. In the
whole cohort, statistically significant associations between high
T-CD45RO and improved DSS (P = .007) as well as DFS (P =
.014) and OS (P = .001) were observed. In the stromal
compartment, association with survival was limited to a trend
(Table 2). Combining the scores in tumor epithelium and stroma
yielded a slightly less significant association with survival
(three-tiered: DSS P = .014, DFS P = .009, OS P = .001)
compared with the epithelial scores.
In both epithelial and stromal compartments, we found major
prognostic differences between histological subgroups. For patients
with SCC, there was a highly significant association between
T-CD45RO and DSS (P = .0003), DFS (P b .001), and OS
(P = .0003). In the SCC subgroup, the positive impact of high
T-CD45RO on DSS was present across pathological stages [I:
P = .088 (trend), II: P = .005, IIIA: P = .011] and in both
cohorts (UNN: P = .003, NH: P = .022). The S-CD45RO
score had a significant prognostic value in SCC but less so than
T-CD45RO (Table 2). Also, when combining the epithelial and
stromal scores, the association with survival became stronger
(DSS, DFS, OS: all P ≤ .0003) than in the whole cohort. In
contrast, we found no significant association with survival in
ADC and LCC (not presented).
With regard to CD8, we found high density of CD8+ TILs to be
associated with improved survival, most significant in the stromal
compartment and limited to the SCC subgroup (Table 2).Univariate Analyses: Prognostic Impact of Epithelial
CD45RO+ Combined with CD8+ TILs in Tumor and Stroma
When combining the two most significant settings for each of the
two markers, T-CD45RO and S-CD8, a highly significant
association with patient outcome emerged, achieving a stratification
of patient survival surpassing that of each marker (Table 2). A
stratification into three categories: high + high (high T-CD45RO
score and high S-CD8 score), intermediate (high + low or low + high),
or low + low, revealed substantial differences in DSS, DFS, and OS
(all: P b .001). Again, when stratifying into histological subgroups,
low P values for all outcomes were seen in the SCC subgroup (DSS,
DFS, OS: all P b .001) and across all pathological stages (DSS: I: P =
.025, II: P b .001, III: P = .001). For ADC, no association with
survival was found (Figure 2, Table 2).
Figure 3 illustrates how combining the immune score (coexpres-
sion T-CD45RO and S-CD8) with pathological (TNM) stage for
SCCNSCLC increases stratification and adds prognostic impact. The
median 5-year DSS of the four TNM-I subgroups was 87% (n = 75),
75% (n = 106), 44% (n = 71), and a dismal 0% (n = 19) versus 82%
(pStage I), 60% (pStageII), and 23% (pStage IIIA). According to the
immune score (T-CD45RO and S-CD8), there is a 40% difference in
5-year DSS within the pStage I patient group (low + low: 47%,
intermediate: 74%, high + high: 87%). In pStage II, the differences in
5-year DSS are even greater (0%, 51%, 73%) when stratified for
immune score. In fact, the TNM-I approach facilitates the
identification of the most disadvantageous prognostic patient
subgroup, which did not reach 5-year DSS (Figure 3, C and D; 16
of 19 patients died of lung cancer within 30 months).
Multivariate Analysis: Independent Prognostic Impact of
T-CD45RO and S-CD8
All significant demographic, clinicopathologic, and lymphocyte
infiltrate variables from the univariate analyses were entered into the
multivariate Cox regression analysis. Data are presented in Table 3. In
the whole cohort, high T-CD45RO was an independent prognostic
Figure 2. DSS curves are shown according to density of T-CD45RO
in (A) all patients, (B) SCC, and (C) ADC.
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1.26-2.57, P = .001], DFS (HR 1.79, 95% CI 1.28-2.50, P = .001),
and OS (HR 1.61, 95% CI 1.22-2.13, P = .001). In the SCC
histological subgroup, the prognostic impact for DSS (HR 2.65, 95%
CI 1.64-4.28, P b .001) as well as for DFS (HR 2.36, 95% CI
1.50-3.73) and OS (HR 2.06, 95% CI 1.43-2.96, P b .001) was
further increased.
The coexpression of T-CD45RO and S-CD8 had a highly
significant independent prognostic value in the whole cohort (DSS,
DFS, OS: all P b .001). In the SCC histological subgroup, the HR for
high + high versus intermediate score was 2.08 (95% CI 1.29-3.37,
P = .003), and for high + high versus low + low, it was 6.50 (95% CI
3.54-11.91, P b .001). When stratifying SCC patients into
pathological stages, the combination was significant for DSS in
multivariate analysis for all stages (high + high versus low + low for
pStage I: HR 4.35, P = .012; pStage II: HR 8.24, P b .001; pStage
IIIA: HR 9.52, P = .002) and for both centers (high + high versus low +
low, UNN: HR: 4.82, P = .001; NH: HR 5.94, P b .001).
Discussion
Our study demonstrates a positive association between the presence
of CD45RO+ TILs and survival in a large, unselected, and
representative stage I to IIIA NSCLC patient cohort. For tumors in
the SCC histological subgroup, high in situ density of epithelial
CD45RO+ TILs was a strong prognostic factor for all evaluated end
points (DSS, DFS, and OS) in two different cohorts and in both
univariate and multivariate analyses. When combined with stromal
CD8+ TIL density in SCC, the prognostic impact increased further
and remained an independent prognostic factor across all pathological
stages (I-IIIA).
Well-validated IHC antibodies used for the staining of immune
markers in the routine clinical and research setting were used in this
study. The stainingmethod is simple, and themanual, semiquantitative
manner of IHC scoring was found to be reproducible, with good
interobserver agreement. This demonstrates that simple IHC assess-
ment of immune cell infiltrates in routinely processed and stained tissue
from primary tumors can provide valuable prognostic information.
The presence of TILs related to various compartments within the
tumor is frequently a matter of debate. In the present study, the
prognostic impact of tumor epithelial CD45RO+ TILs clearly
surpasses the stromal prognostic impact, although their densities were
strongly correlated (r = 0.494). Patients with high stromal score (n =
287) rarely presented a low tumor epithelial score (n = 12), fitting the
biological model of TILs infiltrating the epithelial compartment via
the stromal compartment. Interestingly, 148 of the 217 tumors with
low stromal score had a high tumor score, demonstrating that a strong
stromal infiltrate is not a prerequisite for epithelial infiltration, and
separate analysis of the compartments seems required. Although our
study does not offer an explanation for the difference in prognostic
impact depending on location, hopefully it can be explored further in
functional studies.
Evaluating the prognostic impact of TILs in different tumor
localizations is another important issue. Our TMAs represent a
mixture of cores from tissue in the central tumor and at the invasive
margins. Assessing localizations separately, as recommended by the
colorectal Immunoscore worldwide task force [21], could improve the
prognostic impact of immune markers and should be explored for
CD45RO in future NSCLC studies. Evaluating whole slides might
allow inclusion and analysis of areas from both the central tumor and
Figure 3. From TNM to TNM-I in SCC NSCLC. DSS curves of the SCC patient subgroup, according to (A) pathological (TNM) stage and (B)
immunoscore (combination of T-CD45RO and S-CD8 score). The combination of A and B results in a “TNM-I” survival table (C) identifying
subgroups of patients with greatly differing 5-year DSS within the same pathological stages. The colors of the boxes in the table (C)
represent patient subgroups with similar survival [favorable prognosis (green), intermediate-favorable prognosis (light green),
intermediate-poor prognosis (gray), poor prognosis (red)]. Constructing survival curves (DSS) for these patient subgroups (D) illustrates
how the immunoscore adds significant prognostic impact across each pathological stage.
Neoplasia Vol. 17, No. 11, 2015 Paulsen et al. 845the invasive margin and is easily available in the clinical routine.
Nevertheless, for research purposes, TMA techniques appear to be
representative and adequate, and provide a high throughput method
[8]. Finally, digital automated evaluation of IHC staining may
provide important advantages such as standardization and time
efficiency [21].
CD45RO is broadly accepted as the most suitable single marker for
the whole memory T cell population [12,13,22]. Evaluated by
immunochemistry, high expression of CD45RO+ Tmemory cells has
been associated with improved disease-related outcomes in various
human cancers, including esophageal (ADC and SCC) [23,24],
colorectal [5,6,25], endometrial [26], gastric [27,28], ovarian [29],
and hepatocellular cancer [30]. In renal cell carcinoma, it was
associated with worse prognosis [31].
The prognostic effect of the T memory lymphocyte subset in
NSCLC has been reported in few studies. In a study on
tumor-induced bronchus-associated lymphoid tissues in stage I and
IIA NSCLC patient tumors, Dieu-Nosjean et al. [32] reported that
the density of mature dendritic cell, a specific marker of TLS, was
predictive of survival. In 24 evaluated patient samples, they found
CD45RO to be expressed by most CD3+ T cells, whereas the densityof CD45RA+ (naïve T cells) was low, in contrast to the equal
proportions of conventional lymphoid organs. Although no associ-
ation between CD45RO and survival could be found, their results
pointed to TLS-derived memory cells being involved in developing a
central memory and systemic response postsurgery. Goc et al. [33]
also found, in a study on 458 human primary lung tumors (stage I-IV),
that high density of TLS mature dendritic cells correlated with
long-term survival as well as with a strong infiltration of T cells,
predominantly of the effector-memory subtype (CD45RA −
CCR7-CD27+/−CD28+/−, n = 54). Djenidi et al. [34] found
CD8+CD103+ TIL to be characteristic of tissue-resident memory
T cells. Their study suggested CD103 to be involved in recruitment and
activation of tumor-specific T cells in lung tumor islets and that a high
expression of CD103+ TILs correlates with improved stage I NSCLC
patient survival (regardless of localization: epithelial or stromal).
To our knowledge, only one study has reported the prognostic
impact of in situ CD45RO+ TILs in NSCLC patients [22]. In 956
stage I ADC NSCLC patients, Suzuki et al. [14] found no association
between CD45RO+ memory T cells and recurrence-free survival.
Reassuringly, in our study, the result was confirmed for this subgroup
of patients (stage I ADC: n = 101). In general, we observed no
Table 3. Results of Cox Regression Analysis Summarizing Significant Independent Prognostic Factors for DSS
All Patients SCC ADC
HR (95% CI) P HR (95% CI) P HR (95% CI) P
Pathological stage b .001 * b .001 * b .001 *
I 1.00 1.00 1.00
II 1.79 (1.31-2.46) b .001 2.49 (1.53-4.06) b .001 2.20 (1.37-3.53) .001
IIIA 4.08 (2.83-5.89) b .001 7.38 (4.17-13.07) b .001 3.33 (1.94-5.72) b .001
Histology .003 *
SCC 1.00
ADC 1.62 (1.21-2.19) .001*
LCC 1.00 (0.60-1.67) .996
Vascular infiltration .001 .081 * .048*
No 1 1.00 1.00
Yes 1.79 (1.29-2.50) 1.51 (0.95-2.41) 1.72 (1.01-2.94)
Differentiation .006 * .303* .098 *
Well 1.00 1.00 1.00
Moderate 1.75 (1.02-3.01) .042 1.31 (0.59-2.89) .201 1.99 (0.98-4.03)
Poor 2.32 (1.35-3.99) .001 1.69 (0.76-3.78) .507 2.13 (1.06-4.26)
Sex .001* NE .023 *
Female 1.00 1.64 (1.07-2.52)
Male 1.68 (1.24-2.29)
ECOG performance status .005 * NE .003 *
0 1.00 1.00
1 1.54 (1.16-2.03) .003 1.64 (1.08-2.50) .021
2 1.78 (0.99-3.18) .052 3.59 (1.58-8.16) .002
Smoking .013 * NE NE
Never 1.00
Present 0.36 (0.18-0.71) .003
Former 0.41 (0.20-0.82) .012
Margins NE NE .362 *
Free 1.00
Not free 1.42 (0.67-2.93)
T-CD45RO ** .001 * b .001 * NE
High 1.00 1.00
Low 1.80 (1.26-2.57) 2.65 (1.64-4.28)
S-CD45RO ** NE .003 * NE
High 1.00
Low 1.85 (1.23-2.78)
T-CD45RO + S-CD8 ** b .001 * b .001 * NE
High + high 1.00 1.00
Intermediate 1.62 (1.29-2.18) .002 2.08 (1.29-3.37) .003
Low + low 2.43 (1.46-4.02) .001 6.50 (3.54-11.91) b .001
Abbreviation: ECOG, eastern cooperative oncology group; NE, not entered.
* Overall significance as a prognostic factor.
** In separate models.
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regardless of stage or end point.
In contrast, for tumors with SCC histology, we found T-CD45RO
to be a strong positive prognostic factor in uni- and multivariate
analyses across all pathological stages and in both cohorts. The
differences in 5-year DSS, DFS, and OS between high and low
T-CD45RO scores were 27%, 27%, and 23%, respectively.
Interestingly, similar studies in colorectal cancer show increased
prognostic effect of the immune score when combining CD45RO+
and CD8+ TILs [6,35]. Based on recently published results by our
group on S-CD8 as a promising candidate marker for NSCLC
TNM-I [11], patient stratification could be further refined by
combining T-CD45RO score with S-CD8 score (Figure 3B). In the SCC
subgroup, the combined immune score revealed considerable and
significant differences in outcome between the three score groups (high +
high, intermediate, low + low) and was in multivariate analysis a robust
indicator for improved prognosis (Table 3) in all pathological stages.
The marked difference in 5-year DSS of patients across stage I, II,
and IIIA, respectively, clearly illustrates the association between
density of CD45RO+ and CD8+ TILs and outcome (Figure 3D).
This may indicate a potential adjuvant treatment benefit in patientswith low immune score, which calls for further studies. For the most
dismal TNM-I prognosis group (Figure 3, C and D), the demand for
new treatment strategies seems crucial. However, the numbers of
these subgroups are too small to draw firm conclusions.
Preventing postoperative recurrence in patients with NSCLC is
essential to improve prognosis, and recent research fuels great
expectations of immunotherapy as an effective, specific cancer
treatment with less toxicity [36]. Research on the dynamics of
TILs, including memory T cells, before and after anticancer therapy
will be pivotal for assessing their value as predictive markers regarding
adjuvant treatment, including both chemotherapy and immunother-
apy. Induction or maintenance of memory T cells might be a novel
treatment strategy, and ensuring that anticancer treatment does
not inhibit tumor-specific T memory cell subsets should at least
be considered.
Because of its design, this study cannot solve the question of
causality regarding the differences in prognostic impact in histological
subgroups. Associations to factors known to differ between SCC
versus non-SCC NSCLC, such as likelihood of smoking, growth
patterns, pemetrexed sensitivity, antiangiogenic-associated toxicity,
and frequency of response to epidermal growth factor receptors, could
Neoplasia Vol. 17, No. 11, 2015 Paulsen et al. 847be explored in future studies. So should the functional importance of
these markers in NSCLC subgroups.
In summary, our study is the first to reveal T-CD45RO as a strong
prognosticator in NSCLC patients, though limited to the SCC
histological subgroup. Interestingly, when combined with S-CD8,
the independent positive prognostic impact improved convincingly in
all pathological stages (I-IIIA), thus representing a robust immuno-
logical indicator of a significantly improved survival time. Further-
more, within each pathological stage, there were significant survival
differences according to the immune score. CD45RO+ T memory
lymphocytes are valuable prognosticators in NSCLC and are
attractive for supplementing the TNM classification in the routine
clinical setting as well as for research purposes. We propose CD45RO
as a candidate marker for a novel TNM-I in squamous NSCLC.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2015.11.004.
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